Asthma
Drug research and approvals for asthma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 376 studies of asthma are recruiting on ClinicalTrials.gov, Health Canada has authorized 154 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 20 authorised medicines for it.
- Recruiting worldwide: 376
- Trials authorized in Canada: 154
- FDA orphan approvals: 0
- EU medicines: 20
Recruiting Now
Newest start dates first, of 376 recruiting on ClinicalTrials.gov ↗- Chronic Respiratory Disease Participant Engagement StudyNCT07924462 · Not reported · Richmond Research Institute · starts Nov 1, 2026
- Effects of Tele-rehabilitation-Guided Qigong on Children and Adolescents With AsthmaNCT07883967 · Not applicable · Antalya Health Sciences University · starts Oct 15, 2026
- THERMotherapy Against Persistent Bacterial LUNG InfectionsNCT05351242 · Not applicable · Chronic Obstructive Pulmonary Disease Trial Network, Denmark · starts Oct 14, 2026
- A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe AsthmaNCT07746687 · Phase 2 · Janssen Research & Development, LLC · starts Oct 5, 2026
- Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body…NCT07851623 · Phase 1 · Chiesi Farmaceutici S.p.A. · starts Oct 2, 2026
- A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe AsthmaNCT07869043 · Phase 3 · Pfizer · starts Sep 30, 2026
- BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREANCT07570394 · Not reported · AstraZeneca · starts Sep 17, 2026
- A Study to Understand the Accuracy of a New Breathing Device Compared to Standard Testing for Asthma and COPDNCT07253883 · Not reported · Liverpool Heart and Chest Hospital NHS Foundation Trust · starts Sep 15, 2026
- Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 AgonistNCT07718724 · Not applicable · AstraZeneca · starts Sep 5, 2026
- A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and…NCT07645248 · Phase 3 · GlaxoSmithKline · starts Sep 1, 2026
Trials Authorized in Canada
The 10 newest of 154; search them all in Canada trials| Aug 28, 2026 | A phase 2b, multicenter, randomized, double-blind, placebo controlled, dose-ranging trial to evaluate the efficacy and safety of jnj-95597528 for the treatment…JNJ-95597528 | Johnson & Johnson | Pending |
| Jul 27, 2026 | A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of add-on lunsekimig in adolescents and adults with…LUNSEKIMIG (SAR443765) | SANOFI-AVENTIS CANADA INC | Pending |
| May 20, 2026 | The modify study: a phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on…DEPEMOKIMAB (GSK3511294) | GSK | Ongoing |
| Mar 24, 2026 | Evaluating the impact of single dose tiotropium on allergen-induced early asthmatic responseTIOTROPIUM | UNIVERSITY OF SASKATCHEWAN | Pending |
| Nov 25, 2025 | A multinational, investigator-initiated, parallel group, randomised, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of…DUPIXENT | UNIVERSITÉ DE SHERBROOKE | Ongoing |
| Nov 14, 2025 | A randomized, double-blind, placebo-controlled phase 2a study of aro-rage inhalation solution to assess efficacy on small airway dysfunction in…ADS-015 | ARROWHEAD PHARMACEUTICALS, INC. | Ongoing |
| Oct 8, 2025 | A phase 2, multicenter, randomized, double-blind, 52-week study, to investigate the efficacy and safety of brenipatide compared with placebo for the treatment…BRENIPATIDE (LY3537031) | Eli Lilly | Ongoing |
| Oct 3, 2025 | Paxt: pulmonary imaging of mild asthma using 129-xenon mri and tc-99-labeled-carbon-imaging (tc99cimaging)HYPERPOLARIZED XENON-129 | ROBARTS RESEARCH INSTITUTE | Ongoing |
| Sep 19, 2025 | Reverse lung airway and vascular remodeling in asthma remission (renorm)HYPERPOLARIZED XENON-129 | ROBARTS RESEARCH INSTITUTE, WESTERN UNIVERSITY | Ongoing |
| Sep 3, 2025 | Understanding the role of airway mucus occlusions in canadians with asthma, copd and chronic cough (canmuc)HYPERPOLARIZED XENON-129 | MCMASTER UNIVERSITY | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Sep 21, 1989 | TroleandomycinTreatment of severe steroid-requiring asthma. | Szefler, Stanley M. M.D. | Designated |
Medicines Authorised in the EU
Newest first; 15 of 20| Feb 12, 2026 | Exdensurdepemokimab | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| May 16, 2024 | Omlycloomalizumab · biosimilar | Celltrion Healthcare Hungary Kft. | EMA ↗ |
| Sep 19, 2022 | Tezspiretezepelumab | AstraZeneca AB | EMA ↗ |
| Jan 6, 2022 | Riltrava Aerosphereformoterol fumarate dihydrate;glycopyrronium;budesonide | AstraZeneca AB | EMA ↗ |
| Mar 26, 2021 | Seffalair Spiromaxsalmeterol;fluticasone propionate | Teva B.V. | EMA ↗ |
| Dec 9, 2020 | Trixeo Aerosphereformoterol;glycopyrronium bromide;budesonide | AstraZeneca AB | EMA ↗ |
| Jul 3, 2020 | Enerzair Breezhalerindacaterol;glycopyrronium bromide;mometasone | Novartis Europharm Limited | EMA ↗ |
| Jul 3, 2020 | Zimbus Breezhalerindacaterol;glycopyrronium;mometasone furoate | Novartis Europharm Limited | EMA ↗ |
| May 30, 2020 | Atectura Breezhalerindacaterol;mometasone | Novartis Europharm Limited | EMA ↗ |
| May 30, 2020 | Bemrist Breezhalerindacaterol;mometasone | Novartis Europharm Limited | EMA ↗ |
| Apr 3, 2020 | GoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.)budesonide;formoterol fumarate dihydrate | Teva Pharma B.V. | EMA ↗ |
| Jan 8, 2018 | Fasenrabenralizumab | AstraZeneca AB | EMA ↗ |
| Jul 17, 2017 | Trimbowbeclometasone;formoterol;glycopyrronium bromide | Chiesi Farmaceutici S.p.A. | EMA ↗ |
| Aug 15, 2016 | Cinqaeroreslizumab | Teva B.V. | EMA ↗ |
| Dec 1, 2015 | Nucalamepolizumab | GlaxoSmithKline Trading Services Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA